Minutes of the 2nd Meeting of the Pharmaceutical and Medical Device Safety Measures Division, Safety Measures Subcommittee, Fiscal Year 2026

SUMMARY

According to a press release from the Ministry of Health, Labour and Welfare, the "Minutes of the 2nd Meeting of the Pharmaceutical and Medical Device Safety Measures Division, Safety Measures Subcommittee, Fiscal Year 2026" have been announced. This information serves as a reference for management decisions in the hospital, clinic, and medical corporation sectors within the healthcare industry.

📝 EDITOR'S NOTE — A Medical M&A Perspective

Trends in the medical industry directly impact the business succession and M&A strategies of hospitals, clinics, and medical corporations. Changes in the complex management environment, such as revisions to medical fee schedules, successor shortages, labor difficulties, the burden of capital investment, and the advancement of regional medical plans, are forcing medical institutions to make new management decisions.

As an option for addressing successor issues and changes in the management environment,Third-Party Succession M&Ais increasing in importance year by year. Choosing succession over closure or廃業 (business dissolution) allows for the simultaneous achievement of securing transfer value, maintaining staff employment, ensuring continuity of patient care, and preserving regional medical services. The framework of M&A support institutions certified by the Small and Medium Enterprise Agency has also been established, and advisory services specializing in the unique licensing, tax, and labor aspects of the medical industry have become widespread.

Accurate understanding of industry trends and early consultation with experts are key to attracting the best options for management decisions in medical institutions. As an M&A advisory firm specializing in the medical industry, we support medical institutions with free consultations and success-fee-based services.

News Highlights

At the 2nd Pharmaceutical and Medical Device Safety Measures Division, Safety Measures Subcommittee meeting in Fiscal Year 2026, discussions were held regarding the appropriate use of pharmaceuticals and safety measures. In particular, the need to grasp information on drug side effects and actual usage patterns, and to strengthen information provision to healthcare professionals was pointed out. It is also presumed that trends in new drug development and the potential for safety measures utilizing digital technology were mentioned.

M&A Medical Editorial Department’s Perspective

Although this subcommittee meeting is not directly about M&A, it addresses themes directly related to the operational foundation of medical institutions, such as the appropriate use of pharmaceuticals and safety measures. For example, decisions regarding the introduction of new drugs, expansion of indications for existing drugs, or switching to generic drugs can affect the profitability and quality of medical care provided by institutions. In particular, changes in side effect information and precautions discussed at the Safety Measures Subcommittee can pose risks to the business continuity of medical institutions specializing in specific departments or disease areas. When considering M&A, the extent to which a target medical institution has grasped and can respond to these latest safety measure trends is an important evaluation item in due diligence. As this can also influence future drug price revisions and insurance reimbursement reviews, management is constantly required to gather information and establish systems.

Points Raised by This News

Appropriate use and safety measures for pharmaceuticals directly impact the profitability and quality of medical care at healthcare institutions.
Safety measure information is essential for decisions on introducing new drugs and switching to generics.
Changes in side effect information and precautions can pose business continuity risks for specific medical departments.
The response to safety measures is a crucial evaluation item in M&A due diligence.

Practical Questions Arising from This News

Were there any specific pharmaceutical or side effect-related points requiring particular attention at this subcommittee meeting?
How should healthcare institutions keep up with the latest trends in pharmaceutical safety measures?
When considering M&A, how should the acquiring party evaluate the pharmaceutical safety measure system of the target healthcare institution?

If You Feel “Should I Consult Too?”

Are you fully aware of the latest safety measures and trends in appropriate drug use for the pharmaceuticals your institution handles? Considering the potential impact of future drug price revisions, insurance reimbursement, or unexpected side effect risks on business continuity, consulting with experts is effective. Especially if you are considering M&A, the pharmaceutical management system and the ability to respond to safety measures of both potential acquisition and divestiture candidates are important evaluation points. Early consultation can help identify risks and develop countermeasures.

M&A Medical (CentralMedience Co., Ltd.) supports the business succession of medical corporations, hospitals, and clinics with a complete success fee system as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here

📌 Source (Primary Information)

Minutes of the 2nd Meeting of the Pharmaceutical and Medical Device Safety Measures Division, Safety Measures Subcommittee, Fiscal Year 2026

Source: Ministry of Health, Labour and Welfare Press Release

Please see the original article for details.

Regarding trends in medical institutions like this case,

we provide a detailed explanation of the "Medical Succession Guide."

Read the Complete Guide →